<DOC>
	<DOCNO>NCT03015389</DOCNO>
	<brief_summary>This multi-center , prospective , randomize study enroll patient undergo endoscopic surveillance due history histologically confirm dysplasia . A member research team approach potential subject discus participation study , include background propose study , inclusion exclusion criterion , benefit risk procedure follow-up . If interest subject , informed consent form discuss present . The subject must sign consent form prior enrollment . This form prior approval study site 's Institutional Review Board ( IRB ) . Failure obtain informed consent render subject ineligible study .</brief_summary>
	<brief_title>Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis ( WATS3D ) For Detection High Grade Esophageal Dysplasia Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Patients age : â‰¥ 18 year 2 . Patients history Barrett 's associated esophageal dysplasia ( either low highgrade ) confirm histology 3 . Willingness undergo WATS3D random forceps biopsy undergo conventional EGD sedation 4 . Ability provide write , inform consent ( approved IRB ) understand responsibility trial participation 5 . Only patient visible mucosal abnormality time undergo random forceps biopsy WATS3D test esophagus include study 1 . Coagulopathy INR &gt; 2.0 , thrombocytopenia platelet count &lt; 50,000 2 . The subject pregnant planning pregnancy study period 3 . History esophageal gastric surgery Endoscopic Mucosal Resection ( EMR ) 4 . Patients undergone endoscopic ablative therapy 5 . Subject known history unresolved drug alcohol dependency would limit ability comprehend follow instruction relate informed consent , posttreatment instruction , followup guideline 6 . Study patient inadequate WATS3D specimens undergo repeat brush biopsy test exclude study 7 . BE length &lt; 1 cm &gt; 10 cm 8 . Patients within six week receive targeted forceps biopsy and/or EMR 9 . Patients visible mucosal abnormality time WATS3D random biopsy test 10 . Patients visible lesion either submucosal cover clinically intact epithelium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>